Novartis is a Swiss multinational pharmaceutical company headquartered in Basel, specializing in oncology, cardiology, immunology, and infectious diseases.
Is this your business? Add your evidence →
Novartis demonstrates solid operational decarbonization and supply-chain engagement but relies heavily on carbon credits for claimed neutrality. Nature strategy is nascent. A 2022 NGO assessment flagged 'very low integrity' targets—since partially addressed by SBTi validation—and the company retains trade association memberships with poor climate records.
Novartis scores 50/100 (Making progress) on SINK's independent climate assessment, scored from public data only. Fees pay for the review, never the result. Last verified May 2026.
That places Novartis joint 149th of 847 companies scored, and joint 4th of 19 in Healthcare / Pharmaceuticals.
Where Novartis sits among healthcare / pharmaceuticals peers.
Among the 19 major healthcare / pharmaceuticals brands we've scored, Novartis is tied =4th of 19, with 2 others.
Its two lowest-scoring questions, and what the evidence didn't show.
InfluenceMap identified limited direct climate policy engagement; company retains industry association memberships with predominantly negative climate stances.
No quantified nature footprint or deforestation-free commitment published.
A score changes when the evidence does. We use new published evidence at the next rescore. Evidence that isn't public can count through an evidence review.
Use this score in tenders
Send the link, or the one-page score sheet. It links back to this page and every source. Free.
Open the score sheet →Add your evidence, £99
Scored low because little is published? Send us your evidence. A person reviews it and your score reflects what you really do. Done within 5 working days.
Evidence review →Go tender-ready, £495 a year
A yearly rescore, a check of up to 25 key suppliers and a score badge for your website (coming soon).
Get in touch →Strongest on Carbon Footprint — Operations and Energy Source (8/10, 8/10). Weakest on Controversies & Red Flags and Nature & Biodiversity Impact (3/10, 5/10).
The 3 companies in the sector scoring nearest above Novartis.
Smith & Nephew reports genuine 63% absolute emissions cuts (Scope 1+2) and 59% Scope 3 reductions since 2021, backed by third-party verification.
See the breakdown →AstraZeneca has cut operational emissions 77.5% since 2015 and locked in science-based net-zero targets, but absolute supply chain emissions are rising 18.6% from baseline.
See the breakdown →GSK has credible climate infrastructure: verified Scope 1&2 data, SBTi-validated net-zero to 2045, and sector-leading nature disclosures.
See the breakdown →The formula and all 12 sources.
Same ten questions for every company. No private weighting.
SINK = (0.3 × Base + 0.7 × Performance) × Scale12 sources used in this assessment. All publicly available. Each row shows which of the ten questions it informed.
If you believe a source has been misread or a newer version exists, submit a challenge.
Novartis is a Swiss multinational pharmaceutical company headquartered in Basel, specializing in oncology, cardiology, immunology, and infectious diseases. One of the sector's largest by revenue, it operates manufacturing sites globally and maintains extensive supply chains across chemical procurement and active pharmaceutical ingredients.
One email, every Sunday. Score changes, new research, the stories behind the numbers. Free.
No spam. Unsubscribe in one click.
Checking a company?
Search free →Asked to prove you're sustainable?
Get your business scored, free →Been scored?
See what's behind your number →Fees pay for the review, never the result.